References:

**AmnioGraft®**: An established standard therapy
- Expedites patient recovery due to the unique HC-HA/PTX3 complex preserved with the CryoTek™ process:
  - Reduces inflammation
  - Promotes regenerative healing
  - Suppresses pain
- Provides cosmetically superior results
- Is durable and easy to handle

**AmnioGraft® Catalog of Sizes**

<table>
<thead>
<tr>
<th>Catalog Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AG1510</td>
<td>AmnioGraft® 1.5 x 1.0 cm</td>
</tr>
<tr>
<td>AG2015</td>
<td>AmnioGraft® 2.0 x 1.5 cm</td>
</tr>
<tr>
<td>AG2520</td>
<td>AmnioGraft® 2.5 x 2.0 cm</td>
</tr>
<tr>
<td>AG3535</td>
<td>AmnioGraft® 3.5 x 3.5 cm</td>
</tr>
<tr>
<td>AG5050</td>
<td>AmnioGraft® 5.0 x 5.0 cm</td>
</tr>
</tbody>
</table>

**Order AmnioGraft® Today**
Contact your representative for more information
Call 1-888-296-8858 between 9:00 am and 4:00 pm EST, or 1-800-990-1306 between 4:00 pm and 7:00 pm EST, or visit www.biotissue.com.

**Tissue Safety and Quality Assurance**
AmnioGraft® is processed and preserved according to Current Good Tissue Practice (CGTP) and Current Good Manufacturing Practice (CGMP) regulations established by the United States Food & Drug Administration (FDA). Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. AmnioGraft® is processed using a validated, proprietary method to produce AmnioGraft®. The final product is released after microbiological testing yields no growth of microorganisms (aerobic, anaerobic, or fungal). AmnioGraft® is preserved in a validated and patented storage medium.

**Expedite Your Patient’s Recovery**
- Reduce inflammation
- Promote regenerative healing
- Suppress pain
- Achieve superior cosmetic results

**Expedite Recovery**
- Reduce inflammation
- Promote regenerative healing
- Suppress pain
- Achieve superior cosmetic results

**AmnioGraft®**: An established standard therapy for ocular surface reconstruction

**BIOLOGIC OCULAR TRANSPLANTATION GRAFT**

**Tissue Safety and Quality Assurance**
AmnioGraft® is procured and processed according to Current Good Tissue Practice (CGTP) and Current Good Manufacturing Practice (CGMP) regulations established by the United States Food & Drug Administration (FDA). Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation. Placental tissues are retrieved from donor mothers after elective caesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological, and autoimmune diseases and undergo a physical exam to determine the suitability for human transplantation.
Benefits of Expedited Recovery

In many ocular surface diseases and conditions, the ocular surface can become compromised, and as a result, patients may experience pain, vision loss, and an undesirable ocular cosmetic appearance. After surgical intervention, the optimal expedited recovery process involves reduced inflammation, rapid and regenerative healing, suppressed pain, and achieving a superior cosmetic outcome.

Autologous Surgical Grafts in Ocular Surface Reconstruction

Surgical grafts are used to replace and repair damaged or excised host tissue. Autologous surgical grafts provide structural support but do NOT expedite recovery.

This results in a highly inflamed, ocular surface, slow and painful healing, and sub-optimal outcomes.

AmnioGraft® Expedites Recovery

AmnioGraft®, due to its proprietary CryoTek™ processing method, uniquely preserves the heavy chain-hyaluronic acid-PTX3 complex (HC-HA/PTX3) found in the extracellular matrix of the amniotic membrane. This critical component preserved in AmnioGraft®, but absent in conjunctival autografts, provides support but do NOT expedite recovery.

AmnioGraft® Product Features

The active ECM components found within AmnioGraft® allow patients to recover quickly, with minimal inflammation, and return sooner to a normal quality of life.2-4

Primary Pterygium

Key Characteristics of Primary Pterygium: Abnormal growth from the caruncle diagnosed as primary pterygium

- May interfere with patient’s vision
- Undesirable cosmetic appearance

Treatment Strategy:

- Excision removal of pterygium, use of “sealing the gap” technique and transplantation of AmnioGraft® (A)

Results:

- Achieved fast recovery with no pain, excellent cosmetic outcome, and no recurrence at 1-year follow-up (B)

Recurrent Pterygium

Key Characteristics of Recurrent Pterygium: Abnormal growth from the caruncle diagnosed as recurrent pterygium

- May interfere with patient’s vision and ocular motility, causing diplopia
- Undesirable cosmetic appearance

Treatment Strategy:

- Pterygium surgery with “sealing the gap” technique, fornix reconstruction, and multiple-layer AmnioGraft® membrane transplantation (AMT) (A)

Results:

- Achieved fast recovery with restoration of full range of ocular mobility, excellent cosmetic appearance, and no recurrence at 1-year follow-up (B)

Case Studies

Autologous Surgical Grafts X

Surgical grafts replace and repair damaged or excised host tissue but do NOT expedite recovery.

AmnioGraft® X X X X X X

AmnioGraft® expedites recovery by:

- Reducing inflammation 4-7
- Promoting regenerative healing 4-10
- Suppressing pain
- Providing a superior cosmetic outcome for the patient 10

AmnioGraft® is a better choice for your patients

AmnioGraft® is durable and easy to handle.